181 related articles for article (PubMed ID: 30755440)
1. Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8
Viitala M; Virtakoivu R; Tadayon S; Rannikko J; Jalkanen S; Hollmén M
Clin Cancer Res; 2019 Jun; 25(11):3289-3303. PubMed ID: 30755440
[TBL] [Abstract][Full Text] [Related]
2. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R; Rannikko JH; Viitala M; Vaura F; Takeda A; Lönnberg T; Koivunen J; Jaakkola P; Pasanen A; Shetty S; de Jonge MJA; Robbrecht D; Ma YT; Skyttä T; Minchom A; Jalkanen S; Karvonen MK; Mandelin J; Bono P; Hollmén M
Clin Cancer Res; 2021 Aug; 27(15):4205-4220. PubMed ID: 34078651
[TBL] [Abstract][Full Text] [Related]
3. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
4. New tools to prevent cancer growth and spread: a 'Clever' approach.
Hollmén M; Figueiredo CR; Jalkanen S
Br J Cancer; 2020 Aug; 123(4):501-509. PubMed ID: 32595212
[TBL] [Abstract][Full Text] [Related]
5. Clever-1/stabilin-1 controls cancer growth and metastasis.
Karikoski M; Marttila-Ichihara F; Elima K; Rantakari P; Hollmén M; Kelkka T; Gerke H; Huovinen V; Irjala H; Holmdahl R; Salmi M; Jalkanen S
Clin Cancer Res; 2014 Dec; 20(24):6452-64. PubMed ID: 25320356
[TBL] [Abstract][Full Text] [Related]
6. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
7. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
8. Clever-1 positive macrophages in breast cancer.
Mutka M; Virtakoivu R; Joensuu K; Hollmén M; Heikkilä P
Breast Cancer Res Treat; 2022 Oct; 195(3):237-248. PubMed ID: 35917053
[TBL] [Abstract][Full Text] [Related]
9. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
11. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
Bozeman EN; He S; Shafizadeh Y; Selvaraj P
Hum Vaccin Immunother; 2016; 12(2):421-30. PubMed ID: 26308597
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
Cao K; Zhang G; Yang M; Wang Y; He M; Zhang C; Huang Y; Lu J; Liu H
Cancer Res; 2023 Jul; 83(13):2171-2186. PubMed ID: 37172314
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
17. One Clever Macrophage Checkpoint.
Mantovani A; Bonecchi R
Clin Cancer Res; 2019 Jun; 25(11):3202-3204. PubMed ID: 30936124
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages.
Rao E; Hou Y; Huang X; Wang L; Wang J; Zheng W; Yang H; Yu X; Yang K; Bugno J; Ding X; Vokes E; Fu YX; Weichselbaum RR; Liang HL
Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34723044
[TBL] [Abstract][Full Text] [Related]
20. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
